Invasive Fungal Infections

Invasive fungal infections are mycoses that penetrate beyond surface tissues to involve the bloodstream, deep organs, or normally sterile sites. They are serious, often difficult to diagnose, and carry high mortality, occurring predominantly — though not exclusively — in people with impaired immune defences or disrupted barriers.

Definition

An invasive fungal infection is a mycosis in which fungal organisms invade deep tissue, the bloodstream, or other normally sterile sites, as opposed to remaining confined to skin and superficial mucosa.

Scope

This topic covers the concept of invasive (deep, systemic) mycosis, the leading causative groups such as Candida and Aspergillus, the host and barrier factors that permit deep invasion, the diagnostic challenge these infections pose, and the relevance of antifungal resistance. It is reference material and does not provide dosing or individualised management.

Key concepts

• Deep and systemic tissue invasion
• Candidaemia and invasive candidiasis
• Invasive aspergillosis and other mould diseases
• Angioinvasion and dissemination
• Diagnostic difficulty and biomarkers
• Proven, probable, and possible disease categories
• Antifungal resistance

Mechanisms

Invasive disease arises when fungi cross host barriers and the immune defences that normally contain them are insufficient. Candida species frequently enter the bloodstream from the gut or from vascular catheters, while inhaled mould conidia such as Aspergillus may germinate and invade lung tissue and blood vessels, allowing dissemination to other organs including the central nervous system. Neutropenia, impaired phagocyte function, corticosteroid use, and mucosal or skin breaches are central permissive factors. Diagnosis is hampered by non-specific signs and the limited sensitivity of culture, which is why biomarker and molecular tests are used to support standardised proven/probable/possible classifications.

Clinical relevance

Invasive fungal infections are an important cause of death in immunocompromised and critically ill patients, and awareness of the host factors and diagnostic limitations is part of evidence appraisal in infectious diseases. This entry summarises how the disease category is defined and studied and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Several million invasive fungal infections occur worldwide each year, with invasive candidiasis and invasive aspergillosis among the most frequent and lethal. Incidence is concentrated in patients with haematological malignancy, transplant recipients, those in intensive care, and other immunocompromised groups, and outcomes are worsened where antifungal resistance is present.

Evidence & guidelines

Professional societies issue periodically updated guidance on the diagnosis and management of major invasive mycoses; the Infectious Diseases Society of America aspergillosis guideline is one widely cited example. Standardised consensus definitions of proven, probable, and possible invasive disease underpin research and surveillance. Guidance evolves, and current versions should be consulted directly.

History

Invasive mycoses moved from rarity to a major clinical concern across the later twentieth century as intensive chemotherapy, organ and stem-cell transplantation, broad-spectrum antibiotics, indwelling devices, and HIV expanded the immunocompromised population. The development of serologic and molecular biomarkers and of consensus disease definitions reshaped how these infections are recognised and studied.

Debates

How should invasive disease be defined for research and surveillance?

Because culture is insensitive and tissue invasion is hard to confirm, consensus proven/probable/possible categories combine host factors, clinical features, and mycological evidence; the thresholds and the weight given to biomarkers remain subjects of refinement.

Seminal works

• mccarthy-2014
• patterson-2016
• pappas-2018

Frequently asked questions

What makes a fungal infection 'invasive'?

Invasion of deep tissue, the bloodstream, or other normally sterile sites, in contrast with superficial infections that stay confined to skin and mucosal surfaces.

Why are invasive fungal infections hard to diagnose?

Their signs are non-specific and cultures are often insensitive, so diagnosis frequently relies on combining host risk factors, clinical and imaging findings, and biomarker or molecular tests within standardised consensus definitions.